OUR PURPOSE PIONEERING SCIENCE PATIENTS OUR PEOPLE ENVIRONMENT COMMUNITY REPORTING 15 BIOGEN 2021 YEAR IN REVIEW ~ 30 clinical programs across a broad set of disease areas ADUHELM® APPROVED FDA approval of ADUHELM®, the 1 st novel therapy approved for Alzheimer’s disease since 2003 Celebrated 5 -YEAR anniversary of SPINRAZA®, with more than 11,000 people treated PIONEERING SCIENCE Associate Scientist Alvin Meda.